Would you use Ibrutinib plus Venetoclax as second line therapy in relapsed/refractory mantle cell lymphoma?  

The recent NEJM phase II trial http://www.nejm.org/doi/full/10.1056/NEJMoa1715519?query=featured_home looked at a small cohort of 24 patients and showed a significantly higher response rate compared to historical results of ibrutinib monotherapy.

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice